• Prevision Medicine raised a $5.4 million Seed round led by ACE Ventures to commercialize a functional precision medicine cancer test.
• The startup targets hematological malignancies and solid tumors, using a single-cell platform to test living tumor cells against drug libraries.
• Capital earmarked for regulatory clearances, reimbursement coverage, and operational expansion across Europe to support clinical adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ace & Company SA published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.